基于ChAdOx1和MVA的MERS-CoV候选疫苗在小鼠中诱导中和抗体和细胞免疫应答
研究开发了四种基于ChAdOx1和MVA病毒载体的MERS-CoV候选疫苗,均含全长刺突基因,在小鼠中评估单剂或 prime-boost 方案。含tPA的ChAdOx1 MERS诱生的中和抗体高于不含tPA者,单剂可诱导体液和细胞免疫,经MVA MERS加强后中和抗体显著升高。作者认为候选疫苗应在骆驼和临床试验中测试。
要点
- 含tPA的ChAdOx1 MERS诱生的中和抗体高于不含tPA的ChAdOx1 MERS。
- 单剂含tPA的ChAdOx1 MERS诱导体液和细胞免疫,经MVA MERS加强后中和抗体显著升高。
- F11启动子增强MVA MERS的细胞免疫原性,显著高于mH5启动子。
核心结论
- MERS-CoV候选疫苗可通过利用不同病毒载体、不同载体遗传设计或不同免疫方案来优化免疫原性。
- ChAdOx1和MVA载体疫苗已在骆驼和人类中安全评估,这些MERS候选疫苗现应在骆驼和临床试验中测试。
研究设计与样本
- 研究开发了四种基于ChAdOx1和MVA病毒载体的MERS-CoV候选疫苗,每种载体两个候选。
- 所有疫苗含MERS-CoV全长刺突基因;ChAdOx1 MERS疫苗含或不含人组织型纤溶酶原激活物基因前导序列(tPA),MVA MERS疫苗含tPA并由mH5或F11启动子驱动刺突基因表达。
- 所有候选疫苗在小鼠模型中评估单剂或prime-boost方案。
主要发现
- 含tPA的ChAdOx1 MERS诱生的中和抗体高于不含tPA的ChAdOx1 MERS。
- 单剂含tPA的ChAdOx1 MERS诱导体液免疫和细胞免疫,经MVA MERS加强后中和抗体显著升高至更高水平。
- 单剂含tPA的ChAdOx1 MERS的体液免疫原性与两剂MVA MERS(亦含tPA)相当。
- 含mH5或F11启动子的MVA MERS诱导相似抗体水平,但F11启动子使MVA MERS的细胞免疫原性显著增强至更高幅度。
临床怎么用
- 作者认为这些MERS候选疫苗现应在骆驼和临床试验中测试。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The Middle East respiratory syndrome coronavirus (MERS-CoV) has infected more than 1900 humans, since 2012. The syndrome ranges from asymptomatic and mild cases to severe pneumonia and death. The virus is believed to be circulating in dromedary camels without notable symptoms since the 1980s. Therefore, dromedary camels are considered the only animal source of infection. Neither antiviral drugs nor vaccines are approved for veterinary or medical use despite active research on this area. Here, we developed four vaccine candidates against MERS-CoV based on ChAdOx1 and MVA viral vectors, two candidates per vector. All vaccines contained the full-length spike gene of MERS-CoV; ChAdOx1 MERS vaccines were produced with or without the leader sequence of the human tissue plasminogen activator gene (tPA) where MVA MERS vaccines were produced with tPA, but either the mH5 or F11 promoter driving expression of the spike gene. All vaccine candidates were evaluated in a mouse model in prime only or prime-boost regimens. ChAdOx1 MERS with tPA induced higher neutralising antibodies than ChAdOx1 MERS without tPA. A single dose of ChAdOx1 MERS with tPA elicited cellular immune responses as well as neutralising antibodies that were boosted to a significantly higher level by MVA MERS. The humoral immunogenicity of a single dose of ChAdOx1 MERS with tPA was equivalent to two doses of MVA MERS (also with tPA). MVA MERS with mH5 or F11 promoter induced similar antibody levels; however, F11 promoter enhanced the cellular immunogenicity of MVA MERS to significantly higher magnitudes. In conclusion, our study showed that MERS-CoV vaccine candidates could be optimized by utilising different viral vectors, various genetic designs of the vectors, or different regimens to increase immunogenicity. ChAdOx1 and MVA vectored vaccines have been safely evaluated in camels and humans and these MERS vaccine candidates should now be tested in camels and in clinical trials.
引用
- Alharbi NK, Padron-Regalado E, Thompson CP, et al. ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice. Vaccine. 2017. PMID: 28579232. doi:10.1016/j.vaccine.2017.05.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。